ALKBH5 has been reported to be upregulated in a variety of cancers including breast (Zhang et al., 2016), lung (Sun et al., 2022), and epithelial ovarian cancers (Nie et al., 2021), where it plays an oncogenic role in tumor progression. Here, ALKBH5 is linked to neoplasm.